Comment on “Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case control study”

To the Editor: We read with great interest the study performed by Varpuluoma et al.1 The authors conducted a nationwide case-control study aiming to estimate the prevalence of administration of oral antidiabetics among patients with bullous pemphigoid (BP) versus among matched control subjects. No association was found between exposure to any oral diabetes medications other than dipeptidyl peptidase-4 inhibitors (DPP4is) and the development of BP.1 DPP4is, particularly vildagliptin, have emerged as a risk factor for the development of BP.

https://ift.tt/2z59jqG